-
Mashup Score: 0Lutetium-177-PSMA-617 Does Not Prevent Response to Subsequent mCRPC Therapies - Renal and Urology News - 17 day(s) ago
The FDA indicated lutetium-177-PSMA-617 for patients with PSMA-positive mCRPC already treated with an ARPI and a taxane.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 0Rectal Spacers During Prostate Radiotherapy May Preserve Erectile Function - Renal and Urology News - 18 day(s) ago
A recent study explored the association between rectal spacer use and the US county-level prevalence of erectile dysfunction.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet-
Use of rectal spacers during prostate radiotherapy is associated with a lower prevalence of erectile dysfunction. ASCO #GU25 #pcsm https://t.co/ZYyhTOvwiF
-
-
Mashup Score: 0
Patients with intermediate-risk prostate cancer had a 15-year prostate cancer–specific survival rate of 91% with EBRT, with or without short-term ADT.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
EBRT Regimens Show Long-Term Survival Outcomes in Prostate Cancer @ASCO #GU25 #pcsm https://t.co/KcK128GXHq
-
-
Mashup Score: 0
The TALAPRO-2 trial revealed promising survival data for patients with metastatic CRPC treated with talazoparib and enzalutamide.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
A significant overall survival benefit has been observed in patients with metastatic castration-resistant prostate cancer treated with the combination of talazoparib and enzalutamide. #GU25 #pcsm | @neerajaiims @ASCO https://t.co/FwF0UQbvg6
-
-
Mashup Score: 1
First-line therapy with olaparib plus abiraterone demonstrated clinical benefit in rPFS and OS in mCRPC harboring germline and somatic BRCA mutations.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Olaparib Plus Abiraterone Improves Radiographic PFS and OS in BRCA+ mCRPC @ASCO @cancermtl #GU25 #pcsm https://t.co/QmtuKuNMCU
-
-
Mashup Score: 0Composite Gene Expression Score Shows Potential to Predict Bavdegalutamide Benefit in mCRPC - 27 day(s) ago
A low composite gene expression score was associated with improved outcomes in patients with mCRPC who received bavdegalutamide.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Composite Gene Expression Score Shows Potential to Predict Bavdegalutamide Benefit in mCRPC @massgeneralnews @asco #GU25 #pcsm https://t.co/0BAqxpHYG9
-
Using an ARPI or taxane after 177Lu-PSMA-617 can produce a robust PSA response in patients with mCRPC. ASCO #GU25 #pcsm https://t.co/LxHDXwxcJi